Search Results for: Schizophrenia

1632 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
CTSB and BAG6 cathepsin B BCL2-associated athanogene 6
  • Toll-Like Receptors Cascades
  • Trafficking and processing of endosomal TLR
  • Collagen formation
  • Collagen degradation
  • MHC class II antigen presentation
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Adaptive Immune System
  • Innate Immune System
  • 2-Aminoethanimidic Acid
  • 3-Amino-4-Oxybenzyl-2-Butanone
  • 3-Methylphenylalanine
  • N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline
  • 2-Pyridinethiol
  • Diphenylacetic Acid
  • N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-2-Methyl-Butane
  • N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-
  • N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCINE
  • BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE
  • METHYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE
  • N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ALANINE
  • N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ISOLEUCINE
  • N-({(2S,3S)-3-[(BENZYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINE
MAPK1 and NTRK3 mitogen-activated protein kinase 1 neurotrophic tyrosine kinase, receptor, type 3
  • phospho-PLA2 pathway
  • Ca-dependent events
  • Signaling by FGFR in disease
  • Cellular Senescence
  • ERKs are inactivated
  • CREB phosphorylation through the activation of Ras
  • Signaling by EGFRvIII in Cancer
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • SOS-mediated signalling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • SHC-mediated signalling
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Regulation of actin dynamics for phagocytic cup formation
  • TRIF-mediated TLR3/TLR4 signaling
  • Senescence-Associated Secretory Phenotype (SASP)
  • Signaling by VEGF
  • Signalling to RAS
  • Downstream signal transduction
  • Toll Like Receptor 3 (TLR3) Cascade
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Frs2-mediated activation
  • Transmission across Chemical Synapses
  • Axon guidance
  • IRS-mediated signalling
  • L1CAM interactions
  • Oncogene Induced Senescence
  • VEGFA-VEGFR2 Pathway
  • Activated TLR4 signalling
  • VEGFR2 mediated cell proliferation
  • GRB2 events in ERBB2 signaling
  • RSK activation
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • NCAM signaling for neurite out-growth
  • Signalling to p38 via RIT and RIN
  • RAF/MAP kinase cascade
  • Innate Immune System
  • Signaling by Insulin receptor
  • ERKs are inactivated
  • Signal transduction by L1
  • Insulin receptor signalling cascade
  • PLC beta mediated events
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • SHC-related events
  • G-protein mediated events
  • Signaling by FGFR
  • Thrombin signalling through proteinase activated receptors (PARs)
  • ARMS-mediated activation
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Signal attenuation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • ERK/MAPK targets
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Signaling by GPCR
  • Mitotic Prophase
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • FCERI mediated MAPK activation
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • DAP12 signaling
  • Toll Like Receptor 9 (TLR9) Cascade
  • ERK/MAPK targets
  • Negative regulation of FGFR signaling
  • Signaling by PDGF
  • DAP12 interactions
  • Opioid Signalling
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Signaling by Leptin
  • Growth hormone receptor signaling
  • Signalling to ERKs
  • Prolonged ERK activation events
  • ERK activation
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • IGF1R signaling cascade
  • Recycling pathway of L1
  • M Phase
  • Toll Like Receptor TLR6:TLR2 Cascade
  • IRS-related events triggered by IGF1R
  • Activation of the AP-1 family of transcription factors
  • MyD88 cascade initiated on plasma membrane
  • ERK activation
  • Downstream signaling of activated FGFR
  • Advanced glycosylation endproduct receptor signaling
  • Post NMDA receptor activation events
  • Signalling by NGF
  • SOS-mediated signalling
  • MAP kinase activation in TLR cascade
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • Cellular response to heat stress
  • Regulation of HSF1-mediated heat shock response
  • NGF signalling via TRKA from the plasma membrane
  • MyD88-independent cascade
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell Cycle, Mitotic
  • ERK2 activation
  • SHC1 events in EGFR signaling
  • FRS2-mediated cascade
  • IRS-mediated signalling
  • Oxidative Stress Induced Senescence
  • ERK2 activation
  • Nuclear Events (kinase and transcription factor activation)
  • Isoproterenol
  • Arsenic trioxide
  • Olomoucine
  • Phosphonothreonine
  • Purvalanol
  • SB220025
  • N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
  • (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
  • 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
  • (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
PLA2G2A and BAG6 phospholipase A2, group IIA (platelets, synovial fluid) BCL2-associated athanogene 6
  • Acyl chain remodelling of PG
  • Acyl chain remodelling of PE
  • Synthesis of PA
  • Metabolism of lipids and lipoproteins
  • Acyl chain remodelling of PI
  • Phospholipid metabolism
  • Glycerophospholipid biosynthesis
  • Acyl chain remodelling of PC
  • Acyl chain remodelling of PS
  • Indomethacin
  • Diclofenac
  • Ginkgo biloba
  • 1,4-Butanediol
  • 1-{2-[2-(2-Methoxyethoxy)Ethoxy]Ethoxy}-4-(1,1,3,3-Tetramethylbutyl)Benzene
  • N-Tridecanoic Acid
  • [3-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Propyl-]-Phosphonic Acid
  • 4-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Butyric Acid
  • 1-Benzyl-5-Methoxy-2-Methyl-1h-Indol-3-Yl)-Acetic Acid
  • 6-Phenyl-4(R)-(7-Phenyl-Heptanoylamino)-Hexanoic Acid
  • Elaidoylamide
  • 1-Octadecyl-2-Acetamido-2-Deoxy-Sn-Glycerol-3-Phosphoethylmethyl Sulfide
  • (S)-5-(4-Benzyloxy-Phenyl)-4-(7-Phenyl-Heptanoylamino)-Pentanoic Acid
  • Suramin
MAPK1 and HDAC4 mitogen-activated protein kinase 1 histone deacetylase 4
  • phospho-PLA2 pathway
  • Ca-dependent events
  • Signaling by FGFR in disease
  • Cellular Senescence
  • ERKs are inactivated
  • CREB phosphorylation through the activation of Ras
  • Signaling by EGFRvIII in Cancer
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • SOS-mediated signalling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • SHC-mediated signalling
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Regulation of actin dynamics for phagocytic cup formation
  • TRIF-mediated TLR3/TLR4 signaling
  • Senescence-Associated Secretory Phenotype (SASP)
  • Signaling by VEGF
  • Signalling to RAS
  • Downstream signal transduction
  • Toll Like Receptor 3 (TLR3) Cascade
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Frs2-mediated activation
  • Transmission across Chemical Synapses
  • Axon guidance
  • IRS-mediated signalling
  • L1CAM interactions
  • Oncogene Induced Senescence
  • VEGFA-VEGFR2 Pathway
  • Activated TLR4 signalling
  • VEGFR2 mediated cell proliferation
  • GRB2 events in ERBB2 signaling
  • RSK activation
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • NCAM signaling for neurite out-growth
  • Signalling to p38 via RIT and RIN
  • RAF/MAP kinase cascade
  • Innate Immune System
  • Signaling by Insulin receptor
  • ERKs are inactivated
  • Signal transduction by L1
  • Insulin receptor signalling cascade
  • PLC beta mediated events
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • SHC-related events
  • G-protein mediated events
  • Signaling by FGFR
  • Thrombin signalling through proteinase activated receptors (PARs)
  • ARMS-mediated activation
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Signal attenuation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • ERK/MAPK targets
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Signaling by GPCR
  • Mitotic Prophase
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • FCERI mediated MAPK activation
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • DAP12 signaling
  • Toll Like Receptor 9 (TLR9) Cascade
  • ERK/MAPK targets
  • Negative regulation of FGFR signaling
  • Signaling by PDGF
  • DAP12 interactions
  • Opioid Signalling
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Signaling by Leptin
  • Growth hormone receptor signaling
  • Signalling to ERKs
  • Prolonged ERK activation events
  • ERK activation
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • IGF1R signaling cascade
  • Recycling pathway of L1
  • M Phase
  • Toll Like Receptor TLR6:TLR2 Cascade
  • IRS-related events triggered by IGF1R
  • Activation of the AP-1 family of transcription factors
  • MyD88 cascade initiated on plasma membrane
  • ERK activation
  • Downstream signaling of activated FGFR
  • Advanced glycosylation endproduct receptor signaling
  • Post NMDA receptor activation events
  • Signalling by NGF
  • SOS-mediated signalling
  • MAP kinase activation in TLR cascade
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • Cellular response to heat stress
  • Regulation of HSF1-mediated heat shock response
  • NGF signalling via TRKA from the plasma membrane
  • MyD88-independent cascade
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell Cycle, Mitotic
  • ERK2 activation
  • SHC1 events in EGFR signaling
  • FRS2-mediated cascade
  • IRS-mediated signalling
  • Oxidative Stress Induced Senescence
  • ERK2 activation
  • Nuclear Events (kinase and transcription factor activation)
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Signaling by NOTCH
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by NOTCH1
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Isoproterenol
  • Arsenic trioxide
  • Olomoucine
  • Phosphonothreonine
  • Purvalanol
  • SB220025
  • N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
  • (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
  • 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
  • (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
PARP1 and NFKB1 poly (ADP-ribose) polymerase 1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • TGFBR1 LBD Mutants in Cancer
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Loss of Function of TGFBR1 in Cancer
  • Generic Transcription Pathway
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • SMAD4 MH2 Domain Mutants in Cancer
  • Signaling by the B Cell Receptor (BCR)
  • NF-kB is activated and signals survival
  • Downstream TCR signaling
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Cellular Senescence
  • RIP-mediated NFkB activation via ZBP1
  • Toll Like Receptor TLR6:TLR2 Cascade
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • Activated TLR4 signalling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Downstream signaling events of B Cell Receptor (BCR)
  • FCERI mediated NF-kB activation
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 5 (TLR5) Cascade
  • ZBP1(DAI) mediated induction of type I IFNs
  • p75NTR signals via NF-kB
  • Transcriptional regulation of white adipocyte differentiation
  • MyD88 dependent cascade initiated on endosome
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • Toll Like Receptor 9 (TLR9) Cascade
  • Innate Immune System
  • Regulated proteolysis of p75NTR
  • Signalling by NGF
  • TRIF-mediated TLR3/TLR4 signaling
  • Cytosolic sensors of pathogen-associated DNA
  • Senescence-Associated Secretory Phenotype (SASP)
  • Cytokine Signaling in Immune system
  • p75 NTR receptor-mediated signalling
  • MyD88-independent cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • Signaling by Interleukins
  • TCR signaling
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Interleukin-1 processing
  • Toll Like Receptor 3 (TLR3) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • Activation of NF-kappaB in B cells
  • Fc epsilon receptor (FCERI) signaling
  • TRAF6 mediated NF-kB activation
  • Interleukin-1 signaling
  • Adaptive Immune System
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Carba-Nicotinamide-Adenine-Dinucleotide
  • NU1025
  • Nicotinamide
  • 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone
  • 3-Methoxybenzamide
  • 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
  • 3,4-Dihydro-5-Methyl-Isoquinolinone
  • 2-(3\'-Methoxyphenyl) Benzimidazole-4-Carboxamide
  • 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE
  • (2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium
  • trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium
  • 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
  • Thalidomide
  • Pranlukast
  • Triflusal
EGFR and ANXA1 epidermal growth factor receptor annexin A1
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • G alpha (q) signalling events
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • Class A/1 (Rhodopsin-like receptors)
  • GPCR ligand binding
  • Metabolic disorders of biological oxidation enzymes
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • Peptide ligand-binding receptors
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • G alpha (i) signalling events
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
  • Amcinonide
  • Hydrocortisone
  • Dexamethasone
PARP1 and TCF4 poly (ADP-ribose) polymerase 1 transcription factor 4
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • TGFBR1 LBD Mutants in Cancer
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Loss of Function of TGFBR1 in Cancer
  • Generic Transcription Pathway
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • SMAD4 MH2 Domain Mutants in Cancer
  • CDO in myogenesis
  • Myogenesis
  • Carba-Nicotinamide-Adenine-Dinucleotide
  • NU1025
  • Nicotinamide
  • 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone
  • 3-Methoxybenzamide
  • 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
  • 3,4-Dihydro-5-Methyl-Isoquinolinone
  • 2-(3\'-Methoxyphenyl) Benzimidazole-4-Carboxamide
  • 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE
  • (2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium
  • trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium
  • 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
EGFR and RIN2 epidermal growth factor receptor Ras and Rab interactor 2
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
EGFR and ANKS1B epidermal growth factor receptor ankyrin repeat and sterile alpha motif domain containing 1B
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
RXRA and NFKB1 retinoid X receptor, alpha nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
  • Bile acid and bile salt metabolism
  • Metabolism of lipids and lipoproteins
  • Nuclear Receptor transcription pathway
  • Metabolic disorders of biological oxidation enzymes
  • Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)
  • Generic Transcription Pathway
  • Endogenous sterols
  • Synthesis of bile acids and bile salts
  • Orphan transporters
  • Defective FMO3 causes Trimethylaminuria (TMAU)
  • Signaling by Retinoic Acid
  • Recycling of bile acids and salts
  • Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
  • Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
  • Defective CYP19A1 causes Aromatase excess syndrome (AEXS)
  • Regulation of pyruvate dehydrogenase (PDH) complex
  • Pyruvate metabolism
  • Synthesis of bile acids and bile salts via 27-hydroxycholesterol
  • Defective MAOA causes Brunner syndrome (BRUNS)
  • Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)
  • Activation of gene expression by SREBF (SREBP)
  • The citric acid (TCA) cycle and respiratory electron transport
  • Transcriptional activation of mitochondrial biogenesis
  • PPARA activates gene expression
  • Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)
  • Organelle biogenesis and maintenance
  • Import of palmitoyl-CoA into the mitochondrial matrix
  • Pyruvate metabolism and Citric Acid (TCA) cycle
  • Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)
  • Phase 1 - Functionalization of compounds
  • RORA activates circadian gene expression
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)
  • Cytochrome P450 - arranged by substrate type
  • Transcriptional regulation of white adipocyte differentiation
  • Biological oxidations
  • Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)
  • Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)
  • Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)
  • REV-ERBA represses gene expression
  • Defective CYP1B1 causes Glaucoma
  • Mitochondrial biogenesis
  • Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)
  • Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)
  • Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)
  • Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
  • Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)
  • YAP1- and WWTR1 (TAZ)-stimulated gene expression
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Signaling by the B Cell Receptor (BCR)
  • NF-kB is activated and signals survival
  • Downstream TCR signaling
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Cellular Senescence
  • RIP-mediated NFkB activation via ZBP1
  • Toll Like Receptor TLR6:TLR2 Cascade
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • Activated TLR4 signalling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Downstream signaling events of B Cell Receptor (BCR)
  • FCERI mediated NF-kB activation
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 5 (TLR5) Cascade
  • ZBP1(DAI) mediated induction of type I IFNs
  • p75NTR signals via NF-kB
  • Transcriptional regulation of white adipocyte differentiation
  • MyD88 dependent cascade initiated on endosome
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • Toll Like Receptor 9 (TLR9) Cascade
  • Innate Immune System
  • Regulated proteolysis of p75NTR
  • Signalling by NGF
  • TRIF-mediated TLR3/TLR4 signaling
  • Cytosolic sensors of pathogen-associated DNA
  • Senescence-Associated Secretory Phenotype (SASP)
  • Cytokine Signaling in Immune system
  • p75 NTR receptor-mediated signalling
  • MyD88-independent cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • Signaling by Interleukins
  • TCR signaling
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Interleukin-1 processing
  • Toll Like Receptor 3 (TLR3) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • Activation of NF-kappaB in B cells
  • Fc epsilon receptor (FCERI) signaling
  • TRAF6 mediated NF-kB activation
  • Interleukin-1 signaling
  • Adaptive Immune System
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Adapalene
  • Bexarotene
  • Acitretin
  • Alitretinoin
  • Etodolac
  • Etretinate
  • (5BETA)-PREGNANE-3,20-DIONE
  • 2-chloro-5-nitro-N-phenylbenzamide
  • 1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • tributylstannanyl
  • Thalidomide
  • Pranlukast
  • Triflusal
RXRA and ARNTL retinoid X receptor, alpha aryl hydrocarbon receptor nuclear translocator-like
  • Bile acid and bile salt metabolism
  • Metabolism of lipids and lipoproteins
  • Nuclear Receptor transcription pathway
  • Metabolic disorders of biological oxidation enzymes
  • Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)
  • Generic Transcription Pathway
  • Endogenous sterols
  • Synthesis of bile acids and bile salts
  • Orphan transporters
  • Defective FMO3 causes Trimethylaminuria (TMAU)
  • Signaling by Retinoic Acid
  • Recycling of bile acids and salts
  • Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
  • Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
  • Defective CYP19A1 causes Aromatase excess syndrome (AEXS)
  • Regulation of pyruvate dehydrogenase (PDH) complex
  • Pyruvate metabolism
  • Synthesis of bile acids and bile salts via 27-hydroxycholesterol
  • Defective MAOA causes Brunner syndrome (BRUNS)
  • Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)
  • Activation of gene expression by SREBF (SREBP)
  • The citric acid (TCA) cycle and respiratory electron transport
  • Transcriptional activation of mitochondrial biogenesis
  • PPARA activates gene expression
  • Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)
  • Organelle biogenesis and maintenance
  • Import of palmitoyl-CoA into the mitochondrial matrix
  • Pyruvate metabolism and Citric Acid (TCA) cycle
  • Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)
  • Phase 1 - Functionalization of compounds
  • RORA activates circadian gene expression
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)
  • Cytochrome P450 - arranged by substrate type
  • Transcriptional regulation of white adipocyte differentiation
  • Biological oxidations
  • Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)
  • Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)
  • Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)
  • REV-ERBA represses gene expression
  • Defective CYP1B1 causes Glaucoma
  • Mitochondrial biogenesis
  • Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)
  • Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)
  • Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)
  • Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
  • Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)
  • YAP1- and WWTR1 (TAZ)-stimulated gene expression
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • REV-ERBA represses gene expression
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • RORA activates circadian gene expression
  • Adapalene
  • Bexarotene
  • Acitretin
  • Alitretinoin
  • Etodolac
  • Etretinate
  • (5BETA)-PREGNANE-3,20-DIONE
  • 2-chloro-5-nitro-N-phenylbenzamide
  • 1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • tributylstannanyl
RXRA and HDAC4 retinoid X receptor, alpha histone deacetylase 4
  • Bile acid and bile salt metabolism
  • Metabolism of lipids and lipoproteins
  • Nuclear Receptor transcription pathway
  • Metabolic disorders of biological oxidation enzymes
  • Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)
  • Generic Transcription Pathway
  • Endogenous sterols
  • Synthesis of bile acids and bile salts
  • Orphan transporters
  • Defective FMO3 causes Trimethylaminuria (TMAU)
  • Signaling by Retinoic Acid
  • Recycling of bile acids and salts
  • Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
  • Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
  • Defective CYP19A1 causes Aromatase excess syndrome (AEXS)
  • Regulation of pyruvate dehydrogenase (PDH) complex
  • Pyruvate metabolism
  • Synthesis of bile acids and bile salts via 27-hydroxycholesterol
  • Defective MAOA causes Brunner syndrome (BRUNS)
  • Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)
  • Activation of gene expression by SREBF (SREBP)
  • The citric acid (TCA) cycle and respiratory electron transport
  • Transcriptional activation of mitochondrial biogenesis
  • PPARA activates gene expression
  • Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)
  • Organelle biogenesis and maintenance
  • Import of palmitoyl-CoA into the mitochondrial matrix
  • Pyruvate metabolism and Citric Acid (TCA) cycle
  • Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)
  • Phase 1 - Functionalization of compounds
  • RORA activates circadian gene expression
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)
  • Cytochrome P450 - arranged by substrate type
  • Transcriptional regulation of white adipocyte differentiation
  • Biological oxidations
  • Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)
  • Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)
  • Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)
  • REV-ERBA represses gene expression
  • Defective CYP1B1 causes Glaucoma
  • Mitochondrial biogenesis
  • Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)
  • Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)
  • Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)
  • Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
  • Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)
  • YAP1- and WWTR1 (TAZ)-stimulated gene expression
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Signaling by NOTCH
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by NOTCH1
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Adapalene
  • Bexarotene
  • Acitretin
  • Alitretinoin
  • Etodolac
  • Etretinate
  • (5BETA)-PREGNANE-3,20-DIONE
  • 2-chloro-5-nitro-N-phenylbenzamide
  • 1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • tributylstannanyl
KIT and CSF2RA v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage)
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • Regulation of KIT signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signaling by PDGF
  • Signalling by NGF
  • DAP12 interactions
  • GAB1 signalosome
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Signaling by GPCR
  • G-protein beta:gamma signalling
  • Cytokine Signaling in Immune system
  • GPCR downstream signaling
  • Signaling by Interleukins
  • Interleukin receptor SHC signaling
  • G beta:gamma signalling through PI3Kgamma
  • Interleukin receptor SHC signaling
  • GPVI-mediated activation cascade
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Sorafenib
  • Imatinib
  • Dasatinib
  • Sunitinib
  • Phosphonotyrosine
  • Adenosine-5\'-Diphosphate
  • Nilotinib
  • Pazopanib
  • Regorafenib
  • Ponatinib
  • Sargramostim
CASP3 and TRAF3 caspase 3, apoptosis-related cysteine peptidase TNF receptor-associated factor 3
  • SMAC binds to IAPs
  • SMAC-mediated dissociation of IAP:caspase complexes
  • SMAC-mediated apoptotic response
  • Cytochrome c-mediated apoptotic response
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Degradation of the extracellular matrix
  • Role of DCC in regulating apoptosis
  • Activation of caspases through apoptosome-mediated cleavage
  • Activation of DNA fragmentation factor
  • Apoptotic factor-mediated response
  • Programmed Cell Death
  • Intrinsic Pathway for Apoptosis
  • Signalling by NGF
  • Apoptotic cleavage of cellular proteins
  • Cell death signalling via NRAGE, NRIF and NADE
  • Apoptotic execution phase
  • p75 NTR receptor-mediated signalling
  • Stimulation of the cell death response by PAK-2p34
  • Apoptotic cleavage of cell adhesion proteins
  • Signaling by Hippo
  • Apoptosis induced DNA fragmentation
  • Extrinsic Pathway
  • NADE modulates death signalling
  • Activated TLR4 signalling
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • TRAF3-dependent IRF activation pathway
  • Toll-Like Receptors Cascades
  • Negative regulators of RIG-I/MDA5 signaling
  • TRIF-mediated TLR3/TLR4 signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • MyD88-independent cascade
  • Innate Immune System
  • Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
  • Minocycline
  • 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
  • 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
  • methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
  • 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
  • [N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID
  • 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
  • (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
  • (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
  • N-[3-(2-fluoroethoxy)phenyl]-N\'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
PLG and ENO1 plasminogen enolase 1, (alpha)
  • Signaling by PDGF
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Activation of Matrix Metalloproteinases
  • Dissolution of Fibrin Clot
  • Platelet degranulation
  • Degradation of the extracellular matrix
  • Response to elevated platelet cytosolic Ca2+
  • Platelet activation, signaling and aggregation
  • Orphan transporters
  • Gluconeogenesis
  • Glucose metabolism
  • Myoclonic epilepsy of Lafora
  • Glycogen storage diseases
  • Glycolysis
  • Metabolism of carbohydrates
  • Alteplase
  • Urokinase
  • Reteplase
  • Anistreplase
  • Tenecteplase
  • Streptokinase
  • Tranexamic Acid
  • Aminocaproic Acid
  • Bicine
  • Aprotinin
VEGFA and GPC1 vascular endothelial growth factor A glypican 1
  • VEGF binds to VEGFR leading to receptor dimerization
  • Cellular response to hypoxia
  • VEGF ligand-receptor interactions
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by VEGF
  • Response to elevated platelet cytosolic Ca2+
  • Platelet degranulation
  • Platelet activation, signaling and aggregation
  • Regulation of gene expression by Hypoxia-inducible Factor
  • MPS IIIB - Sanfilippo syndrome B
  • Diseases of glycosylation
  • Defective B4GALT7 causes EDS, progeroid type
  • Axon guidance
  • Heparan sulfate/heparin (HS-GAG) metabolism
  • MPS I - Hurler syndrome
  • MPS IX - Natowicz syndrome
  • Chondroitin sulfate/dermatan sulfate metabolism
  • Defective SLC26A2 causes chondrodysplasias
  • Glycosaminoglycan metabolism
  • Inactivation of Cdc42 and Rac
  • Defective CHST14 causes EDS, musculocontractural type
  • Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
  • Defective PAPSS2 causes SEMD-PA
  • Activation of Rac
  • MPS IIIA - Sanfilippo syndrome A
  • Myoclonic epilepsy of Lafora
  • Defective CHST6 causes MCDC1
  • Glycogen storage diseases
  • MPS IIID - Sanfilippo syndrome D
  • A tetrasaccharide linker sequence is required for GAG synthesis
  • MPS IIIC - Sanfilippo syndrome C
  • Retinoid metabolism and transport
  • Role of Abl in Robo-Slit signaling
  • Diseases associated with glycosaminoglycan metabolism
  • Mucopolysaccharidoses
  • Defective EXT2 causes exostoses 2
  • MPS II - Hunter syndrome
  • Defective B3GAT3 causes JDSSDHD
  • Defective CHST3 causes SEDCJD
  • Defective EXT1 causes exostoses 1, TRPS2 and CHDS
  • Diseases associated with visual transduction
  • MPS IV - Morquio syndrome A
  • Visual phototransduction
  • MPS IV - Morquio syndrome B
  • Defective CHSY1 causes TPBS
  • MPS VII - Sly syndrome
  • Metabolism of carbohydrates
  • Signaling by Robo receptor
  • HS-GAG biosynthesis
  • HS-GAG degradation
  • MPS VI - Maroteaux-Lamy syndrome
  • Bevacizumab
  • Minocycline
  • Gliclazide
  • Carvedilol
  • Ranibizumab
  • Pyroglutamic Acid
  • Tris(Hydroxymethyl)Aminomethane
  • Vandetanib
  • Dalteparin
  • Aflibercept
KIT and PTPRU v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog protein tyrosine phosphatase, receptor type, U
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • Regulation of KIT signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signaling by PDGF
  • Signalling by NGF
  • DAP12 interactions
  • GAB1 signalosome
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Signaling by SCF-KIT
  • Sorafenib
  • Imatinib
  • Dasatinib
  • Sunitinib
  • Phosphonotyrosine
  • Adenosine-5\'-Diphosphate
  • Nilotinib
  • Pazopanib
  • Regorafenib
  • Ponatinib
PPARD and HDAC4 peroxisome proliferator-activated receptor delta histone deacetylase 4
  • Regulation of pyruvate dehydrogenase (PDH) complex
  • Pyruvate metabolism
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Signaling by Retinoic Acid
  • Import of palmitoyl-CoA into the mitochondrial matrix
  • Pyruvate metabolism and Citric Acid (TCA) cycle
  • Nuclear Receptor transcription pathway
  • The citric acid (TCA) cycle and respiratory electron transport
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Signaling by NOTCH
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by NOTCH1
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Icosapent
  • Treprostinil
  • Sulindac
  • Bezafibrate
  • Heptyl-Beta-D-Glucopyranoside
  • (11E)-OCTADEC-11-ENOIC ACID
  • (2S)-2-{3-[({[2-fluoro-4-(trifluoromethyl)phenyl]carbonyl}amino)methyl]-4-methoxybenzyl}butanoic acid
  • 2-({[3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]carbonyl}amino)benzoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • {4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy}acetic acid
VEGFA and NRP1 vascular endothelial growth factor A neuropilin 1
  • VEGF binds to VEGFR leading to receptor dimerization
  • Cellular response to hypoxia
  • VEGF ligand-receptor interactions
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by VEGF
  • Response to elevated platelet cytosolic Ca2+
  • Platelet degranulation
  • Platelet activation, signaling and aggregation
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signal transduction by L1
  • CHL1 interactions
  • Axon guidance
  • Semaphorin interactions
  • Signaling by VEGF
  • Sema3A PAK dependent Axon repulsion
  • Neurophilin interactions with VEGF and VEGFR
  • L1CAM interactions
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • Bevacizumab
  • Minocycline
  • Gliclazide
  • Carvedilol
  • Ranibizumab
  • Pyroglutamic Acid
  • Tris(Hydroxymethyl)Aminomethane
  • Vandetanib
  • Dalteparin
  • Aflibercept
FGF1 and NRP1 fibroblast growth factor 1 (acidic) neuropilin 1
  • Signaling by the B Cell Receptor (BCR)
  • Phospholipase C-mediated cascade
  • Signaling by FGFR in disease
  • SHC-mediated cascade
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Signaling by FGFR2 mutants
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • PI3K/AKT activation
  • PI-3K cascade
  • Signaling by activated point mutants of FGFR1
  • Signaling by FGFR1 mutants
  • PI3K Cascade
  • Negative regulation of FGFR signaling
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • Signaling by ERBB4
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • Activated point mutants of FGFR2
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • FGFR4 ligand binding and activation
  • Signaling by EGFR
  • Signaling by FGFR3 mutants
  • Downstream signal transduction
  • Signaling by activated point mutants of FGFR3
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by FGFR mutants
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • IRS-mediated signalling
  • PIP3 activates AKT signaling
  • IGF1R signaling cascade
  • IRS-related events triggered by IGF1R
  • PI3K events in ERBB2 signaling
  • FGFR1b ligand binding and activation
  • Downstream signaling of activated FGFR
  • FGFR3b ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR ligand binding and activation
  • FGFR2b ligand binding and activation
  • Signaling by Insulin receptor
  • Innate Immune System
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • FGFR3 ligand binding and activation
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • FRS2-mediated cascade
  • FGFR2 ligand binding and activation
  • IRS-mediated signalling
  • FGFR1 ligand binding and activation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • PI3K Cascade
  • Signal transduction by L1
  • CHL1 interactions
  • Axon guidance
  • Semaphorin interactions
  • Signaling by VEGF
  • Sema3A PAK dependent Axon repulsion
  • Neurophilin interactions with VEGF and VEGFR
  • L1CAM interactions
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • Pentosan Polysulfate
  • Amlexanox
  • Sucrose Octasulfate
  • Formic Acid
  • O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • Naphthalene Trisulfonate
  • Pazopanib
  • 5-AMINO-NAPHTALENE-2-MONOSULFONATE

Page 4 out of 82 pages